Utilisation of antimicrobials used to treat bacterial pneumonia in principal referral hospitals during the COVID-19 pandemic, Australia, 2020
DOI:
https://doi.org/10.33321/cdi.2022.46.6Keywords:
AMS, surveillance, pneumonia, COVID-19, antimicrobial stewardship, antimicrobial resistanceAbstract
Figure 4 of this article is in error due to truncation of one data series. Please refer to this report’s Erratum (https://doi.org/10.33321/cdi.2022.46.50) to view the corrected Figure 4.
Background
Concerns have been raised internationally, regarding possible increased antimicrobial use during the COVID-19 pandemic and the potential impact on antimicrobial resistance. This analysis aimed to investigate hospital usage rates of broad-spectrum antibacterial agents used to treat community-acquired pneumonia (CAP) and/or hospital-acquired pneumonia (HAP) in Australian principal referral hospitals during 2020. Secondly, usage rates in Victoria were compared with equivalent national rates.
Methods
Monthly antimicrobial dispensing data for all 31 Australian principal referral hospitals were analysed for the period January 2019 to December 2020. Grams of antimicrobial agents used were converted into the World Health Organization (WHO) assigned metric ‘Defined Daily Dose’ (DDD). Using the hospital activity metric Occupied Bed Days (OBD), a standardised usage density rate was calculated (in units of DDD / 1,000 OBD).
Results
The typical expected seasonal trend in aggregate usage rates, for antibacterials used in the treatment of CAP, was not evident in 2020. Overall usage of doxycycline, azithromycin, amoxicillin and cefuroxime decreased in principal referral hospitals compared to 2019. Aggregated monthly usage rates for broad-spectrum agents used to treat HAP increased nationally, on average, by 5.0% in 2020 compared to 2019. Victoria’s second COVID-19 wave (July–October 2020) coincided with higher usage rates of antibacterials used for CAP.
Conclusion
Public health interventions introduced to limit the spread of SARS-CoV-2 infections may have had unintended benefits on other respiratory infection rates. The drop in hospital usage of antibacterials typically used to treat CAP suggests that the number of cases of pneumonia acquired in the community requiring hospitalisation was markedly reduced in 2020.
Downloads
References
Cong W, Poudel AN, Alhusein N, Wang H, Yao G, Lambert H. Antimicrobial use in COVID-19 patients in the first phase of the SARS-CoV-2 pandemic: a scoping review. Antibiotics (Basel) . 2021;10(6):745. doi: https://doi.org/10.3390/antibiotics10060745.
Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect . 2020;26(12):1622–9. doi: https://doi.org/10.1016/j.cmi.2020.07.016.
Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. J. Infect . 2020;81(2):266–75. doi: https://doi.org./10.1016/j.jinf.2020.05.046.
Monnet DL, Harbarth S. Will coronavirus disease (COVID-19) have an impact on antimicrobial resistance? Euro Surveill . 2020;25(45). doi: https://doi.org/10.2807/1560-7917.ES.2020.25.45.2001886.
Rawson TM, Wilson RC, Holmes A. Understanding the role of bacterial and fungal infection in COVID-19. Clin Microbiol Infect . 2021;27(1):9–11.
Vijay S, Bansal N, Rao BK, Veeraraghavan B, Rodrigues C, Wattal C et al. Secondary infections in hospitalised COVID-19 patients: Indian experience. Infect Drug Resist . 2021;14:1893–903.
Australian Institute of Health and Welfare (AIHW). Australian hospital peer groups . Canberra: Australian Government, AIHW; 16 November 2015. Available from: https://www.aihw.gov.au/reports/hospitals/australian-hospital-peer-groups.
World Health Organization (WHO). ATC/DDD Index. [Online database.] Oslo: WHO Collaborating Centre for Drug Statistics Methodology, Norwegian Institute of Public Health; 2021. [Accessed on 6 July 2021.] Available from: https://www.whocc.no/atc_ddd_index/.
National Health and Medical Research Council (NHMRC), Australian Research Council (ARC), Universities Australia. National Statement on Ethical Conduct in Human Research 2007 (Updated 2018) . Canberra: NHMRC, ARC, Universities Australia; 2018. Available from: https://www.nhmrc.gov.au/about-us/publications/national-statement-ethical-conduct-human-research-2007-updated-2018.
Victorian Government. Victorian COVID-19 data. [Website.] Melbourne: Victorian Government; 2021. [Accessed on 7 September 2021.] Available from: https://www.coronavirus.vic.gov.au/victorian-coronavirus-covid-19-data.
SA Health, Australian Commission on Safety and Quality in Health Care (ACSQHC). National Antimicrobial Utilisation Surveillance Program: 2019 Key Findings . Sydney: ACSQHC; March 2021. Available from: https://www.safetyandquality.gov.au/publications-and-resources/resource-library/2019-annual-report-national-antimicrobial-utilisation-surveillance-program-nausp.
Todd IMF, Miller JE, Rowe SL, Burgner DP, Sullivan SG. Changes in infection-related hospitalisations in children following pandemic restrictions: an interruped time-series analysis of total population data. Int J Epidemiol . 2021. doi: https://doi.org/10.1093/ije/dyab101.
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2022 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
